Steven Simmons, MD
Ophthalmology · Slingerlands, NYNPI 1932157559
Payments from drug & device makers
Across 793 payments — averaging $562.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338K
- Aerie Pharmaceuticals, Inc.$45K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$36K
- Carl Zeiss Meditec USA, Inc.$12K
- Carl Zeiss Meditec, Inc.$10K
- Glaukos Corporation$4K
- plus $2K from 12 others
What the payments were for
- Consulting fees$29,5459%
- Speaking & faculty fees$227,87867%
- Travel & lodging$47,48714%
- Food & beverage$14,3084%
- Education$400%
- Gifts$9,2993%
- Other$11,5783%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 552 | $338,218 |
| Aerie Pharmaceuticals, Inc. | 59 | $45,153 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 57 | $35,662 |
| Carl Zeiss Meditec USA, Inc. | 2 | $11,578 |
| Carl Zeiss Meditec, Inc. | 3 | $9,644 |
| Glaukos Corporation | 10 | $3,841 |
| Bausch & Lomb Americas Inc. | 39 | $676 |
| Alcon | 28 | $627 |
| Tarsus Pharmaceuticals, Inc. | 17 | $233 |
| Sun Pharmaceutical Industries Inc. | 8 | $179 |
| Kala Pharmaceuticals, Inc. | 5 | $92 |
| Novartis | 4 | $74 |
| Dompe US, Inc. | 2 | $63 |
| Thea Pharma Inc. | 2 | $45 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Linus Health, Inc. | 1 | $18 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$204,000
- COMBIGAN$70,676
- Rocklatan$44,373
- Rhopressa$37,052
- VYZULTA$34,887
- ALPHAGAN P$18,958
- LUMERA 300$11,578
- LUMERA$9,299
- RESTASIS$5,750
- DURYSTA$1,375
- XEN GLAUCOMA TREATMENT SYSTEM$373
- XEN$239
- iStent infinite Trabecular Micro-Bypass System Model iS3$115
How this compares
$446,175 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 717 | $411,415 |
| Alphagan PBrimonidine Tartrate | 368 | $184,899 |
| VyzultaLatanoprostene Bunod | 66 | $47,348 |
| CombiganBrimonidine Tartrate/Timolol | 91 | $44,894 |
| RestasisCyclosporine | 30 | $39,975 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 190 | $36,104 |
| RhopressaNetarsudil Mesylate | 43 | $31,302 |
| Bromfenac Sodium | 70 | $28,523 |
| Brimonidine Tartrate | 120 | $28,313 |
| IlevroNepafenac | 24 | $26,342 |
| ProlensaBromfenac Sodium | 21 | $22,592 |
| Brinzolamide | 91 | $21,406 |
| Betoptic SBetaxolol Hcl | 25 | $20,043 |
| TafluprostTafluprost/Pf | 100 | $18,514 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 61 | $11,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $338,218 | $681,1831,206 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $676 | $47,34866 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $45,153 | $31,30243 claims |
| NovartisIlevro | $74 | $26,34224 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $35,662 | $22,59221 claims |
| AlconAzopt | $627 | $9,07020 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $92 | $6,76212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Slingerlands
- Robert SchultzeSlingerlands$153K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.